● Recruiting

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Condition: Lung Cancer · Sponsor: Samsung Medical Center

PhasePhase 2

Planned participants43

Who can joinAll sexes, 30 Years to 75 Years

Healthy volunteersNo

About this study

This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Sehoon Lee, MD · 82-2-3410-1132 · sehoon.lee119@gmail.com

Always discuss trial participation with your own doctor first.

Locations (2)

SMC	Seoul, Kangnamgu, South Korea	Recruiting
Samsung medical center	Seoul, South Korea	Suspended

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04591002